Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The polymorphic oxidation of beta-adrenoceptor antagonists. Clinical pharmacokinetic considerations.

Clinical pharmacokinetics - 1 Jan 2000

Lennard M S, Tucker G T, Woods H F

Abstract excerpt

Wide variability in response to some drugs such as debrisoquine can be attributed largely to genetic polymorphism of their oxidative metabolism. Most beta-blockers undergo extensive oxidation. Anecdotal reports of high plasma concentrations of certain beta-blockers in poor metabolisers (PMs) of debrisoquine have claimed that the oxidation of these drugs is under polymorphic control. Subsequently, controlled...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Asthma
Share to Debrisoquin
Share to Hypertension

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to In Vitro Techniques

Share to Kinetics

Share to Oxidation-Reduction

Share to Phenotype

Share to Polymorphism, Genetic

Source

Identifiers

PMID: 2868819
DOI: 10.2165/00003088-198611010-00001

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The polymorphic oxidation of beta-adrenoceptor antagonists. Clinical pharmacokinetic considerations.PMID 2868819Read ↗

Clinical consequences of polymorphic drug oxidation.Semantic proximity Read ↗

Debrisoquine phenotype and the pharmacokinetics and beta-2 receptor pharmacodynamics of metoprolol and its enantiomers.Semantic proximity Read ↗

Genetically determined adverse drug reactions involving metabolism.Semantic proximity Read ↗

Influence of debrisoquine hydroxylation phenotype on the pharmacokinetics of mexiletine.Semantic proximity Read ↗

Similar effect of oxidation deficiency (debrisoquine polymorphism) and quinidine on the apparent volume of distribution of (+/-)-metoprolol.Semantic proximity Read ↗

Stereoselective disposition of carvedilol is determined by CYP2D6.Semantic proximity Read ↗

[Determination of oxidative phenotype in a sample population and correlation with the pharmacokinetics of propafenone].Semantic proximity Read ↗

The role of genetically determined polymorphic drug metabolism in the beta-blockade produced by propafenone.Semantic proximity Read ↗

[Knowledge about metabolic capacity is important in drug therapy].Semantic proximity Read ↗

Clinical implications of the competitive inhibition of the debrisoquin-metabolizing isozyme by quinidine.Semantic proximity Read ↗

Polymorphic debrisoquin metabolism in a Turkish population.Semantic proximity Read ↗

Pharmacogenetic explanation for excessive beta-blockade following timolol eye drops. Potential for oral-ophthalmic drug interaction.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.